# OnCo record myricx-bio (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/myricx-bio/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "myricx-bio" ;
  schema:name "Myricx Bio"@en ;
  schema:description "Myricx Bio invented a new kind of cancer-killing payload, which blocks an enzyme tumour cells need to survive, and attaches it to antibodies that carry it into tumours. Novartis bought the London company in 2026 for 1.1 billion dollars up front."@en ;
  schema:url <https://onco.cc/companies/myricx-bio/>, <https://myricxbio.com/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://myricxbio.com/>, <https://www.novartis.com/news/media-releases/novartis-agrees-acquire-myricx-bio-advancing-next-generation-antibody-drug-conjugate-innovation-novel-nmti-payload-expanding-options-cancer-patients> ;
  schema:addressCountry "GB" ;
  onco:sections <https://onco.cc/fronts/adcs/> ;
  onco:technologies <https://onco.cc/technologies/adc/> ;
  onco:targets <https://onco.cc/targets/b7h3/>, <https://onco.cc/targets/her2/> .